Key insights
- Personalis (PSNL) promoted Richard Chen to president, expanding his role to integrate R&D with commercial operations in MRD testing. This strategic shift towards commercialization, particularly with the NeXT Personal platform, could positively influence the company's growth and market position within the precision oncology sector. However, the impact on the broader US equity market is limited.
FREMONT, Calif. - Personalis Inc. (NASDAQ:PSNL) announced Tuesday the promotion of Richard Chen to president while he continues serving as chief medical officer. The genomics company, with a market capitalization of $743 million, has seen its stock surge 79% over the past year despite recent volatility.
Chen will oversee the integration of the company’s research and development capabilities, biopharma services, reimbursement, quality systems and medical affairs, according to a press release statement. The genomics company focuses on precision oncology and minimal residual disease testing.
Under Chen’s scientific leadership, Personalis developed the NeXT Personal platform for MRD testing. The platform detects cancer at levels the company describes as below previously achievable thresholds.
"Rich has been the principal architect of our most significant product and technology leaps, including NeXT Personal, and designed the clinical evidence strategy that has accelerated adoption of our ultrasensitive MRD tests," said Chris Hall, chief executive officer of Personalis.
Chen holds expertise in genomic medicine and machine learning. His expanded role aims to align the company’s research and development with integration of its technology into pharmaceutical drug trials and physician workflows.
"Our goal is clear: to make ultrasensitive MRD testing the standard of care for every cancer patient, ensuring earlier detection and better outcomes," Chen said.
The Fremont, California-based company provides genomic testing services for cancer management, combining tumor and normal profiling with algorithms to detect minimal residual disease and cancer recurrence.
The announcement comes as Personalis transitions its focus from research and development toward commercial market operations in MRD testing.
In other recent news, Personalis Inc. reported mixed financial results for the fourth quarter of 2025. The company achieved an earnings per share (EPS) of -0.26, which was better than the forecasted -0.3, representing a positive surprise of 13.33%. However, its revenue came in at $17.3 million, falling short of the expected $17.55 million, a negative surprise of -1.42%. Despite this revenue miss, analysts at Needham raised their price target for Personalis to $12 from $10, maintaining a Buy rating due to recent reimbursement wins. BTIG also reaffirmed a Buy rating with a $13 price target, highlighting the company’s expansion plans for its minimal residual disease (MRD) business. Personalis plans to double its direct sales force for the MRD business from 10 to 20 representatives, working alongside its commercial partner, Tempus. The company’s management provided 2026 revenue guidance that was below consensus expectations. These developments reflect the company’s strategic moves and analyst perspectives, which are crucial for investors to consider.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.